Selumetinib versus chemo for low-grade brain tumor in children
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 2 to 21 at enrollment
- Have a low-grade glioma that is not NF1-related and has no BRAF V600E mutation
- Have not had any tumor treatment besides surgery (no chemo or radiation yet)
- Have measurable tumor on MRI (at least 1 cm² on 2D measurement) and not have an ependymoma
- Have acceptable blood counts, liver/kidney tests, heart/ECG results, and basic eye exam results
- Be able to swallow capsule medication and meet study consent and screening steps at APEC14B1 screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.